California Patent of the Month – February 2025
Raydiant Oximetry, Inc. is revolutionizing fetal health monitoring with a groundbreaking invention that leverages advanced light-based technology and machine learning to non-invasively determine fetal blood oxygen levels. This innovation addresses a critical gap in prenatal care, where current methods, such as fetal heart rate monitoring, often fail to accurately detect fetal distress, leading to unnecessary interventions like Cesarean deliveries. By combining simulations, real-world data, and artificial intelligence, Raydiant Oximetry has developed a system that can predict fetal oxygen saturation with unprecedented precision.
At the core of this invention is a method that uses light applied to a pregnant mammal’s abdomen to gather signals from both the mother and the fetus. These signals are then analyzed using a trained model that has been developed through a combination of simulated and real-world data. The model is trained using simulations of light transmission through tissue models that replicate the optical properties of maternal and fetal tissues, including factors like skin color, melanin content, and blood oxygen levels. This simulated data is then refined with measured in vivo data, creating a robust and accurate predictive tool.
The system can determine both fetal hemoglobin oxygen saturation and tissue oxygen saturation, providing critical insights into fetal health. It can also detect conditions like fetal hypoxia or hypoxemia, alerting healthcare providers to potential risks in real time. By isolating the fetal signal from the composite data, the system ensures that the analysis is focused solely on the fetus, enhancing accuracy.
What sets this invention apart is its ability to overcome the challenges of obtaining sufficient in vivo data for training. By using simulations to generate a vast dataset of scenarios, Raydiant Oximetry has created a model that can be fine-tuned with minimal real-world data, significantly reducing development time and cost. This approach not only accelerates the path to clinical application but also ensures the model’s adaptability to diverse populations and conditions.
This technology has the potential to transform prenatal care, providing clinicians with a reliable, non-invasive tool to monitor fetal well-being and make informed decisions during pregnancy and delivery. By bridging the gap between simulation and real-world application, Raydiant Oximetry is paving the way for safer, more effective maternal and fetal healthcare.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
